Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant PharmovaBOM:530019 +0.21%71 Gross Margin % is 68.61% as of Mar. 2026, which is 4% above its 10-year median of 66.02. GuruFocus rates BOM:530019 with a GF Score™ of 71/100 and a GF Value™ of ₹1,059.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 942 Drug Manufacturers companies, Jubilant Pharmova ranks better than 79.83% on this metric.
The historical rank and industry rank for Jubilant Pharmova's Gross Margin % or its related term are showing as below:
BOM:530019'
s Gross Margin % Range Over the Past 10 Years
Min: 57.53 Med: 66.02 Max: 71.79
Current: 67.85
During the past 13 years, the highestGross Margin % of Jubilant Pharmova was 71.79%. The lowest was 57.53%. And the median was 66.02%.
BOM:530019's Gross Margin % is ranked better than 79.83% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:530019: 67.85
Jubilant Pharmova had a gross margin of 68.61% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Jubilant Pharmova was -0.90% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jubilant Pharmova had a gross margin of 68.61% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jubilant Pharmova Gross Margin % Related Terms
Jubilant Pharmova Gross Margin % Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530019 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jubilant Pharmova (BOM:530019) has a Gross Margin % of 68.61% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jubilant Pharmova and its competitors. This is near median its historical median of 66.02. Over the past decade, Jubilant Pharmova's Gross Margin % has ranged from 57.53 to 71.79. According to the industry distribution chart, Jubilant Pharmova ranks #190 out of 942 companies in the Drug Manufacturers industry, placing it in the top 20.2%.
Is Jubilant Pharmova's Gross Margin % too high?
Jubilant Pharmova's current Gross Margin % of 68.61% is near median its 10-year median of 66.02. Over the past 10 years, this metric has ranged from a low of 57.53 to a high of 71.79. The Drug Manufacturers industry median Gross Margin % is 48.54. Jubilant Pharmova's value of 68.61% is 41.3% above this industry median. Based on the distribution chart, Jubilant Pharmova ranks #190 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jubilant Pharmova has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #190 out of 942 companies for Gross Margin %. This places Jubilant Pharmova in the top 20% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Jubilant Pharmova's value of 68.61% is 41.3% above this benchmark. Historically, Jubilant Pharmova's own Gross Margin % has ranged from 57.53 to 71.79 over the past decade. While the company's 10-year median is 66.02 vs. the industry median of 48.54, Jubilant Pharmova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Gross Margin % of 68.61% is 41.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Gross Margin % is 68.61%, which is near median its own 10-year median of 66.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,059.60, compared to a current price of ₹1,022.25 — trading 3.5% below its estimated fair value. The current Gross Margin % is 68.61%, which is near median its 10-year median of 66.02 and 41.3% above the Drug Manufacturers industry median of 48.54. Jubilant Pharmova's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Gross Margin % is 68.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹1,022.25 is trading 3.5% below its estimated GF Value™ of ₹1,059.60.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
Gross Margin %: 68.61% (near median its 10-year median of 66.02)
GF Value™: ₹1,059.60 vs. price of ₹1,022.25 (3.5% below fair value)
Industry Position: 41.3% above the Drug Manufacturers median (#190 of 942)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
71GF Score
Get the complete analysis for BOM:530019
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
